Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Promote Your Event
Submission Forms
Place an Ad
Weather
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Items For Sale
Jobs
Pets
Auctions, Estate & Garage Sales
Place an ad
Services
Community
Personals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ADC Therapeutics SA
< Previous
1
2
Next >
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
February 02, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in February Investor Conferences
February 01, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
January 03, 2023
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
December 21, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
December 19, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 07, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
November 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
November 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
November 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
October 31, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
September 21, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
September 16, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
August 15, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
August 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
July 27, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
July 20, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
July 11, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
July 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
July 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
June 29, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
June 13, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 12, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics Announces CEO Transition
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
May 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
Tickers
ADCT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.